ZMS-4084 / Simcere - LARVOL DELTA

ZMS-4084, a potent and selective WRN inhibitor induces significant tumor regression and sustained complete responses in MSI-H tumor models (AACR 2026) - "The two clinical-stage WRN inhibitors, HRO761 and RO7589831, have demonstrated the clinical efficacy in phase I trials. In conclusion, we have developed a novel WRN inhibitor, ZMS-4084, which demonstrates robust antitumor activity in both xenograft models and patient-derived organoids representing diverse MSI-H tumor types. Given the synthetic lethality between WRN inhibition and MSI-H status, along with its broad antitumor activity across multiple tumor lineages, ZMS-4084 holds strong potential as a tissue-agnostic therapeutic agent for patients with MSI-H tumors."

IO biomarker • MSI-H • Preclinical • Colorectal Cancer • Microsatellite Instability • Oncology • Ovarian Cancer • Solid Tumor • CDKN1A • MSI • WRN